Reserve Research sells peptides and research compounds strictly for in-vitro research use only. You must be 21 years of age or older and a qualified researcher to proceed.
By entering, you confirm you are purchasing for legitimate research purposes only. These products are not intended for human or veterinary use, diagnosis, or treatment.
Research Use Only (RUO) — All products are sold exclusively for laboratory research purposes. Not for human or veterinary use.
Learn More
Retatrutide is a next-generation synthetic peptide that activates three hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. Each of these plays a distinct role in how the body handles blood sugar, fat storage, and energy expenditure.
By targeting all three receptors simultaneously, retatrutide provides researchers with a model for studying the combined effects of these pathways — something that single or dual-agonist compounds cannot replicate. Research areas of interest include body composition changes, glucose homeostasis, lipid metabolism, liver fat studies, and energy balance regulation.
As the most recently developed compound in the GLP-1 agonist research class, retatrutide represents a frontier area of metabolic research with growing interest from the scientific community.
This vial contains lyophilized Retatrutide at ≥99% purity, verified by independent third-party HPLC and LCMS testing.
Research Summary: The following information is provided for research context only.
Retatrutide is a next-generation synthetic peptide that activates three hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. Each of these plays a distinct role in how the body handles blood sugar, fat storage, and energy expenditure.
By targeting all three receptors simultaneously, retatrutide provides researchers with a model for studying the combined effects of these pathways — something that single or dual-agonist compounds cannot replicate. Research areas of interest include body composition changes, glucose homeostasis, lipid metabolism, liver fat studies, and energy balance regulation.
As the most recently developed compound in the GLP-1 agonist research class, retatrutide represents a frontier area of metabolic research with growing interest from the scientific community.
This vial contains lyophilized Retatrutide at ≥99% purity, verified by independent third-party HPLC and LCMS testing.
Related products
Independently tested for purity — see COA
TB-500
Research-grade TB-500 — synthetic thymosin beta-4 fragment, lyophilized, ≥99% purity. Independently third-party tested with COA included. For research…
MW1885.1 DaBatchTB5010-001
Independently tested for purity — see COA
Semaglutide
Research-grade Semaglutide — GLP-1 receptor agonist analogue, lyophilized, ≥99% purity. Independently third-party tested with COA included. For research…
MW4113.6 DaBatchSEM010-001
Independently tested for purity — see COA
CJC-1295 No DAC + Ipamorelin
This combination vial contains CJC-1295 No DAC (5mg) and Ipamorelin (5mg), two growth hormone secretagogues that work together…
MWCJC-1295 No DAC: 3367.97 Da | Ipamorelin: 711.85 Da
Reviews
There are no reviews yet.